Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Farmers National Banc Corp. Q1 net income up to $16.3M

Farmers National Banc Corp. said first-quarter 2026 net income rose to $16.3 million from $13.6 million a year earlier, while diluted earnings per share held at $0.36. Excluding $4.0 million of acquisition and core conversion costs tied to Middlefield Banc Corp., adjusted net income was $20.0 million and adjusted EPS was $0.45.

The company closed the Middlefield acquisition on March 2, and the deal quickly reshaped the balance sheet. Total assets climbed to $7.18 billion at March 31, 2026, from $5.25 billion at Dec. 31, 2025. Total loans, net of allowance, increased to $4.75 billion from $3.27 billion, while total deposits rose to $5.92 billion from $4.34 billion. Stockholders’ equity increased to $766.9 million from $485.7 million.

Middlefield contributed $1.82 billion of assets, $1.49 billion of loans and $1.49 billion of deposits. Securities available for sale increased to $1.48 billion from $1.34 billion, with Middlefield adding $152.8 million.

Net interest income rose to $42.6 million from $34.2 million a year earlier. Average interest-earning assets increased to $5.55 billion from $4.89 billion. The net interest margin widened to 3.12% from 2.85% in the first quarter of 2025 and from 3.05% in the fourth quarter of 2025. The yield on interest-earning assets improved to 4.89% from 4.74%, while the cost of interest-bearing liabilities fell to 2.35% from 2.52%.

Noninterest income increased to $13.7 million from $10.5 million. Service charge income rose to $2.0 million from $1.8 million, bank owned life insurance income jumped to $1.5 million from $810,000, trust fees increased to $3.0 million from $2.6 million, and investment commissions were up $342,000. Losses on securities sales narrowed sharply to $18,000 from $1.3 million.

Noninterest expense increased to $37.3 million from $28.5 million. Salaries and employee benefits rose to $18.5 million from $16.2 million, occupancy and equipment expense increased by $988,000, FDIC insurance and state and local taxes climbed to $1.6 million from $1.3 million, core processing expense rose to $1.8 million from $1.4 million, and other noninterest expense increased by $650,000 to $3.8 million.

Credit quality weakened in part because of the acquisition. Nonperforming loans increased to $59.9 million from $26.2 million at year-end, and nonperforming loans as a percentage of total loans rose to 1.25% from 0.79%. Loans 30 to 89 days delinquent fell to $14.7 million from $16.9 million. The allowance for credit losses to total loans was 1.14% at March 31, 2026, up from 1.11% at Dec. 31, 2025.

The company recorded a $1.0 million recovery for credit losses and unfunded commitments in the quarter, compared with a $204,000 recovery a year earlier. Annualized net charge-offs were 0.05% of average loans, up from 0.04%.

Liquidity remained substantial, with $788.9 million of additional FHLB borrowing capacity and $446.6 million of available-for-sale securities available for pledging. The loan-to-deposit ratio was 81.1% at quarter-end. Following these announcements, the company's shares moved 0.93%, and are now trading at a price of $13.01. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS